Therapeutic compounds containing an arylacetamide core pending N-benzyl group. Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for inhibiting AMP-activated kinase (AMPK) and their use thereof for treating breast and pancreatic cancer with the specified compounds.

Therapeutic compounds containing an arylacetamide core pending N-benzyl group. Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for inhibiting AMP-activated kinase (AMPK) and their use thereof for treating breast and pancreatic cancer with the specified compounds.

The present invention provides a compound, a composition, a cured object, an optically anisotropic body, and a reflective film which have high refractive index anisotropy Δn and excellent light resistance, and which exhibit liquid crystallinity. The compound of the present invention is a compound represented by General Formula (1). ##STR00001##

The present invention provides a compound, a composition, a cured object, an optically anisotropic body, and a reflective film which have high refractive index anisotropy Δn and excellent light resistance, and which exhibit liquid crystallinity. The compound of the present invention is a compound represented by General Formula (1). ##STR00001##

A compound includes, in a molecule, a structure A represented by the following A and a structure B represented by the following B, in which the compound includes two or more of the structures B in the molecule. A: A structure in which at least one or more aromatic ring structures are included and a total number of π electrons of the aromatic ring structure in the molecule is 8 or more. However, an aryl amine structure represented by a predetermined structure is excluded. B: A fluorine-containing terminal structure represented by a predetermined structural formula.

Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of ##STR00001##
For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I

##STR00001##

which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I

##STR00001##

which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.

Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.